Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA accepts Genzyme's resubmission of Lumizyme

This article was originally published in Scrip

Executive Summary

The US FDA has accepted Genzyme's resubmission of the BLA for its injectable Pompe disease treatment Lumizyme (alglucosidase alfa) seeking approval for the therapy produced at a 4000 litre scale, and has designated it as a class 2 response, which carries a six month review timeline. The user-fee date is on June 17th.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC006557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel